Cell death processes are progressively inactivated during malignant development, in part by loss of tumor suppressors that can promote cell death. The Bin1 gene encodes a nucleocytosolic adaptor protein with tumor suppressor properties, initially identi®ed through its ability to interact with and inhibit malignant transformation by c-Myc and other oncogenes. Bin1 is frequently missing or functionally inactivated in breast and prostate cancers and in melanoma. In this study, we show that Bin1 engages a caspase-independent cell death process similar to type II apoptosis, characterized by cell shrinkage, substratum detachment, vacuolated cytoplasm, and DNA degradation. Cell death induction was relieved by mutation of the BAR domain, a putative eector domain, or by a missplicing event that occurs in melanoma and inactivates suppressor activity. Cells in all phases of the cell cycle were susceptible to death and p53 and Rb were dispensable. Notably, Bin1 did not activate caspases and the broad spectrum caspase inhibitor ZVAD.fmk did not block cell death. Consistent with the lack of caspase involvement, dying cells lacked nucleosomal DNA cleavage and nuclear lamina degradation. Moreover, neither Bcl-2 or dominant inhibition of the Fas pathway had any eect. In previous work, we showed that Bin1 could not suppress cell transformation by SV40 large T antigen. Consistent with this ®nding, we observed that T antigen suppressed the death program engaged by Bin1. This observation was interesting in light of emerging evidence that T antigen has roles in cell immortalization and human cell transformation beyond Rb and p53 inactivation. In support of a link to c-Mycinduced death processes, AEBSF, a serine protease inhibitor that inhibits apoptosis by c-Myc, potently suppressed DNA degradation by Bin1. Our ®ndings suggest that the tumor suppressor activity of Bin1 re¯ects engagement of a unique cell death program. We propose that loss of Bin1 may promote malignancy by blunting death penalties associated with oncogene activation. Oncogene (2000) 19, 4669 ± 4684.
Introduction
Cell suicide programs are crucial to development and homeostasis. A major role of these programs is to stanch inappropriate cell proliferation that can lead to cancer. Indeed, loss of the capacity for programmed cell death (PCD) is a hallmark of the malignant cell. Loss of this capacity is not due to inactivation of the machinery responsible for the major form of PCD, apoptosis, which is minimally comprised of cytochrome c, apoptosis promoting factors (Apafs), and caspases . Instead, it appears that malignant cells suppress or eliminate signals needed to commit to PCD and/or to activate the apoptotic machinery.
How cells commit to die and how malignant cells sidestep this decision are questions of great interest in the areas of programmed cell death and cancer research. Caspase regulation is important, but there is emerging evidence that caspase-independent processes may also have important roles. Death receptors directly activate caspases and cancer cells neutralize these routes by multiple strategies (Ashkenazi and Dixit, 1998) . Mitochondria indirectly regulate caspases, by controlling the release of cytochrome c release and thereby the status of Apaf, which controls the activation of caspase-9 (Green and Reed, 1998) . This route is blunted in cancer cells primarily by alterations in the level of Bcl-2 family proteins, which control cytochrome c release (Chao and Korsmeyer, 1998; Reed et al., 1998; Thompson and Vander Heiden, 1999) , but probably at other levels as well (Ding et al., 1998; Fearnhead et al., 1997) . Caspase activation is clearly sucient for death commitment but whether it is necessary is much less clear. A viable hypothesis is that caspase-independent processes participate in commitment and that caspase activation seals a PCD decision made by the cell (Amarante-Mendes et al., 1998; McCarthy et al., 1997; Thompson and Vander Heiden, 1999) . If so, then caspase-independent processes may be disrupted in cancer cells like caspase activation pathways.
One area of investigation into cancer cell death mechanisms centers on how c-Myc stimulates PCD and why it does not do so in malignancy (Prendergast, 1999) . Oncogenic activation of c-Myc promotes the development of many clinically signi®cant cancers, such as those of the breast, colon, lung, and prostate (Cole, 1986; Garte, 1993; Jenkins et al., 1997) . c-Myc activation usually occurs at later stages in carcinoma in humans and is usually a poor prognostic marker. However, in premalignant cells c-Myc is a robust stimulator of PCD. Therefore, to exploit the growthpromoting aspects of c-Myc, malignant cells must evolve strategies to escape the death penalty associated with its activation. Mechanistic investigations in ®broblast and lymphocyte models have de®ned central roles for the tumor suppressors p53 and p19 ARF , which are frequently inactivated in human cancer (Sherr, 1998) . Whether these genes mediate PCD by c-Myc or sensitize cells to its action is unclear. Nevertheless, it is evident that p53 inactivation does not compromize the ability of c-Myc to drive PCD in epithelial cells (Prendergast, 1999; Sakamuro et al., 1995) , indicating that p53-independent mechanisms are also important. Interestingly, careful investigations have revealed that caspase inhibition or Bcl-2 overexpression does not abolish the ability of c-Myc to commit cells to undergo PCD. Caspase inactivation eliminates nuclear phenotypes characteristic of apoptosis and slows the kinetics of cell death, but it does not abolish all apoptotic phenotypes nor ultimate cellular demise (AmaranteMendes et al., 1998; Cecconi et al., 1998; McCarthy et al., 1997; Soengas et al., 1999; Yoshida et al., 1998) . Similarly, Bcl-2 proteins signi®cantly delay but do not abolish PCD commitment induced by c-Myc either in vitro or in vivo (McCarthy et al., 1997; Trudel et al., 1997; Tsuneoka and Mekada, 2000) . Thus, while c-Myc promotes PCD by activating caspases (Kangas et al., 1998) , and Bcl-2 cooperates with c-Myc to promote malignancy by delaying this process, c-Myc apparently also aects caspase-independent processes that in¯u-ence death commitment. Inactivation of such processes may be important in epithelial cells where c-Myc activation occurs. This may be especially true at stages when malignant cell division is slow and inecient modes of cell death which do not involve caspases may be eective at stanching tumor outgrowth. Thus, inactivation of caspase-independent processes may contribute to tumorigenesis by helping cells escape death penalties associated with activation of c-Myc or other oncogenes (Prendergast, 1999) .
In this study, we investigated a role in PCD for Bin1 (Bridging INtegrator-1), one of an emerging set of cMyc-interacting adaptor proteins that are candidates for regulating c-Myc or mediating its diverse actions in cells . Bin1 function is complex and varied by tissue-speci®c splicing. It was identi®ed initially through its ability to interact with and inhibit malignant transformation by c-Myc (Sakamuro et al., 1996) . Subsequent investigations established that there are two ubiquitous slice isoforms of Bin1 and several other splice forms that are restricted in expression to muscle or brain (Butler et al., 1997; Ramjaun et al., 1997; Tsutsui et al., 1997; Wechsler-Reya et al., 1997b , 1998 . Bin1 polypeptides are related in their terminal domains to amphiphysin, a neuronal protein involved in synaptic vesicle endocytosis, and brain isoforms which are most similar have been termed alternately amphiphysin II or amphiphysin-like (amphl). However, amphiphysin was named for its biochemical properties, rather than its function, and outside the brain Bin1 has functions that are not amphiphysin-like. First, although the brain isoforms of Bin1 are cytosolic, the ubiquitous Bin1 isoforms localize to the nucleus as well as to the cytosol (Kadlec and Pendergast, 1997; Wechsler-Reya et al., 1997a) . Consistent with their nuclear localization, these isoforms functionally interact with the nuclear tyrosine kinase c-Abl as well as with c-Myc (Elliott et al., 1999; Kadlec and Pendergast, 1997) . Second, only brain isoforms of Bin1 include sequences that are required to interact with clathrin and the endocytosis regulatory complex AP-2 (Ramjaun and McPherson, 1998) . Third, muscle-speci®c isoform, which localizes to the nucleus and binds c-Myc, is required for myoblasts to withdraw from the cell cycle and to terminally dierentiate (Mao et al., 1999; Wechsler-Reya et al., 1998) . Lastly, isoforms that localize to the nucleus and bind c-Myc exhibit tumor suppressor properties which are inactivated or missing in malignant melanoma, breast cancer, and prostate cancer (Ge et al., 1999 (Ge et al., , 2000a . In contrast, amphiphysin and brain isoforms of Bin1 lack suppressor activity. Indeed, one way by which Bin1 is functionally inactivated in cancer is by missplicing of one of its brain-speci®c exons (Ge et al., 1999) . Thus, Bin1 has two functions, one of which is linked to nuclear processes that in¯uence cell fate. In this study, we provide evidence that the tumor suppressor properties of Bin1 are related to induction of cell death and that Bin1 participates in a caspaseindependent process similar to type II apoptosis.
Results

Bin1 activates a programmed cell death process in malignant cells
We have shown that reintroduction of Bin1 into human cancer cell lines that lack endogenous expression leads to loss of proliferative capacity and cellular demise (Elliott et al., 1999; Ge et al., 1999 Ge et al., , 2000a Sakamuro et al., 1996) . To investigate this phenomenon in more detail, we used a set of recombinant adenoviral vectors that eciently deliver Bin1 to human cells. One vector was constitutive and used the cytomegalovirus (CMV) early promoter to drive Bin1 expression (Ad-Bin1). A second vector was inducible and allowed Bin1 expression to be controlled by coexpression of Cre recombinase. In this vector, Bin1 cDNA was inserted downstream of a CMV promoter and a stuer cassette¯anked by loxP sites (Ad-MABin1). A matched control virus was also constructed for each system in which a loss-of-function Bin1 gene was expressed (see below). Recombinant viruses were generated in human 293 cells by standard methods. DNA sequencing from ampli®ed viral DNA con®rmed the expected structure of each transgene (data not shown). For control experiments, we also prepared adenoviruses expressing LacZ (Ad-LacZ) or Cre recombinase (Ad-cre) in 293 cells. The host cell line used for infection was HepG2 hepatoma cells, a functionally null cell which lacks endogenous Bin1 expression and is susceptible to Bin1-mediated growth suppression (Elliott et al., 1999; Sakamuro et al., 1996) .
Infections employing Ad-lacZ indicated that a multiplicity of infection (m.o.i.) of 50 ± 100 was required to infect 490% of HepG2 cells exposed to virus in vitro (data not shown). HepG2 cells infected with Ad-Bin1 at 10, 50 or 100 m.o.i. exhibited increasing levels of Bin1 expression as documented by Western analysis of cell extracts prepared and analysed 48 h after infection (see Figure 1a) . Bin1 was detectable within 12 h of infection and reached a maximum by 48 h (see Figure 1b) . When infected under similar conditions, the level of ectopic Bin1 in IMR90 diploid ®broblasts used in control experiments was comparable to that seen in HepG2 cells (see Figure 1c) . Indirect cell immuno¯uorescence experiments indicated that the high level of expression driven by Ad-Bin1 was correlated with localization of Bin1 throughout the cell. To document Bin1 expression from the Creinducible vector Ad-MABin1, we infected HepG2 cell lines that stably expressed Cre recombinase (HepG2/ cre) or that contained only vector sequences (HepG2/ CMV). Bin1 was detected in HepG2/cre cells infected with 50 m.o.i. of Ad-MABin1 (see Figure 1d ). In contrast, Bin1 was not detected after infection of HepG2/CMV cells, where the stuer upstream of Bin1 could not be removed, nor was it detected in either cell line infected with control viruses that lacked an insert (Ad-vect). A constitutive adenoviral vector was also constructed for a loss-of-function mutant of Bin1, termed Bin1DBAR-C, that lacks a.a. 125 ± 206 within the N-terminal BAR domain which is crucial for antineoplastic activity (Elliott et al., 1999) . Extracts derived from cells infected with Ad-Bin1DBAR-C exhibited a polypeptide with the expected apparent mobility of *50 kD (see Figure 1e) . A second smaller polypeptide was also detected at lower levels relative to the Bin1DBAR-C protein on Western blots. The appearance of this polypeptide did not aect the lossof-function of Bin1DBAR-C, which was employed as a negative control for cell death induction (see below). In summary, these experiments validated the adenoviral vectors for constitutive or inducible Bin1 expression in human cells.
HepG2 cells expressing Bin1 displayed striking morphological changes. Cells assumed a rounded, shrunken morphology and exhibited deformations of the plasma membrane before completely detaching from substratum (see Figure 2a) . The changes seen were consistent with induction of PCD like that observed previously (Ge et al., 1999 (Ge et al., , 2000a . Cells infected with Ad-lacZ at similar or higher m.o.i. did not display similar morphologies. No signs of cellular demise were noted following infections of normal human diploid IMR90 ®broblasts with Ad-Bin1 (see Figure 2a ). IMR90 cells showed some enlargement but ow cytometry indicated no signs of cell cycle arrest (data not shown), consistent with previous observations in rodent embryo ®broblasts, Rat1 ®broblasts, or mouse C2C12 myoblasts (Sakamuro et al., 1996; Wechsler-Reya et al., 1998; unpublished observations) . Thus, Bin1 was not grossly toxic to cells, consistent with previous observations (Ge et al., 1999 (Ge et al., , 2000a ; (Sakamuro et al., 1996) but at a level that is undetectable on this exposure of the blot, which illustrates similar steady-state levels of Bin1 in IMR90 or HepG2 cells infected with the same amount of Ad-Bin1. (d) Cre-inducible expression from Ad-MABin1. HepG2 cell lines stably expressing P1 bacteriophage Cre site-speci®c recombinase (HepG2/cre) or containing only vector sequences (HepG2/CMV) were incubated with the virus indicated (m.o.i.=100) and extracts were prepared 48 h later. The transgene in Ad-MABin1 is located downstream of a loxP site-¯anked stuer sequence such that expression occurs only after Cre-induced recombination (see Materials and methods). Ad-vect is a control virus that contain no transgene. (e) Expression of the loss-of-function deletion mutant Bin1DBAR-C. Western analysis was performed using extracts isolated from cells infected with 100 m.o.i. Ad-Bin1 or Ad-Bin1DBAR-C, which lacks anti-transforming and tumor suppressor properties (Elliott et al., 1999b) Sakamuro et al., 1996; Wechsler-Reya et al., 1998) . Induction of the cre-inducible virus Ad-MABin1 produced identical eects. In HepG2/CMV cells, the control virus Ad-vect had little morphological eect, whereas uninduced Ad-MABin1 had a slight eect on cell shape (see Figure 2b ). The eect of the latter virus might re¯ect low leaky expression seen in other cell types infected by Ad-MABin1 (Ge et al., 1999) . However, the uninduced luciferase vector Ad-MA19 produced similar eects and we observed no increase in detached cells using either vector (data not shown), arguing for a nonspeci®c eect of the Ad-MA vector in HepG2 cells. In any case, there was a profound dierence seen in HepG2/cre cells, where Ad-vect had no discernible eect but Ad-MABin1 elicited a dramatic increase in detached cells (see Figure 2b ). Taken together, these results con®rmed that the cytopathic eect elicited by the constitutive Ad-Bin1 vector was not due to nonspeci®c toxicity of the vector system. To explicitly assess cell viability in infected cultures, cells incubated with various m.o.i. of Ad-Bin1 or AdlacZ were harvested 48 h after infection and the proportion of viable cells was determined by trypan blue exclusion. Cells infected with Ad-lacZ at all m.o.i. were 490% viable whereas cells infected with Ad-Bin1 exhibited a linear relationship between m.o.i. and loss of viability (see Figure 2c ). Similar results were obtained using Ad-MABin1 (data not shown). Thus, the cytopathic phenotype elicited by Bin1 was associated with cell death.
We next examined whether cells induced to die by Bin1 exhibited any dierences in endocytosis, because brain-speci®c splice isoforms of Bin1 that localize to the cytosol in dierentiated neurons have been implicated in this process, like the related adaptor protein amphiphysin (David et al., 1996; Ramjaun et al., 1997; Wigge et al., 1997) . Ubiquitous splice isoforms of Bin1 that localize to the nucleus lack brain-speci®c exons required for interaction with clathrin-coated endocytotic vesicles and AP2 (Ramjaun and McPherson, 1998; P. deCamilli, personal communication) . However, while this structural dierence suggested strongly that endocytotic roles were probably brain-speci®c, we wished to explicitly rule out a role for endocytosis in cell death induction by the nonneuronal Bin1 isoform used in these experiments. Fluid-phase or receptor-mediated endocytosis was monitored by comparing the rate of uptake of horseradish peroxidase or¯uorescein-conjugated transferrin, respectively (Barbieri et al., 1998; Benmerah et al., 1998) . No dierences were apparent in the level of uptake of either reagent in cells infected with Ad-Bin1 or Ad-LacZ (data not shown). These observations supported the expectation that the endocytotic function of the Bin1 gene is regulated by alternate splicing and that splice isoforms that localize to the nucleus do not have these roles (Kadlec and Prendergast, 1997; Sakamuro et al., 1996; Wechsler-Reya et al., 1997a , 1998 . We concluded that the ability of Bin1 to induce cell death was unrelated to eects on endocytosis.
To begin to de®ne the basis for cell death, we analysed HepG2 cells by¯ow cytometry following terminal transferase-catalyzed dUTP labeling of nicked DNA ends (TUNEL assay). Cells were infected with increasing m.o.i. of adenoviral vector and harvested for propidium iodide staining, TUNEL assay, and¯ow cytometry 48 h later. A dose-dependent increase in the proportion of TUNEL-positive cells was observed after Ad-Bin1 infection (see Figure 2d ). TUNEL positivity was detected in cells in all phases of the cell cycle as indicating by propidium iodide staining. An increase in cells with sub-G1 phase DNA occurred in the TUNELpositive population with similar kinetics. A time-course experiment con®rmed observations that the appearance of TUNEL-positive cells and the accumulation of cells with sub-G1 phase DNA began 24 ± 36 h after infection, corresponding to a time approximately 12 ± 24 h after Bin1 expression (see Figure 2e ). This experiment also highlighted the ®nding that apoptotic cells (as de®ned by TUNEL positivity) emerged from all phases of the cell cycle. Taken together, these results suggested that Bin1 induced a programmed cell death (PCD) process. Similar experiments performed with the inducible vector con®rmed these observations and con®rmed that they were dependent on Bin1 expression rather than a nonspeci®c eect of the adenoviral vector (data not shown). The features of DNA degradation seen in¯ow cytometry experiments paralleled the kinetics of morphological features of apoptosis and loss of viability. In multiple trials using each vector system, no reproducible eects of Bin1 on the distribution of cells in the cell cycle were noted, consistent with the observation that TUNEL-positive cells emerged from all phases. Taken together, the results suggested that Bin1 engaged a PCD process that could be initiated at any point in the cell cycle, similar to c-Myc and other oncogenes (Evan et al., 1992) .
BAR domain is crucial for Bin1 to induce cell death
The Bin1 BAR domain is crucial to inhibit transformation of rodent ®broblasts by c-Myc and to suppress the proliferation of HepG2 cells (Elliott et al., 1999b) . To determine whether this domain was also crucial for death activity, we infected cells with Ad-Bin1DBAR-C, which expresses the loss-of-function mutant Bin1D BAR-C (Elliott et al., 1999) . Ad-Bin1DBAR-C did not elicit the cell detachment and cytopathic phenotype produced by Ad-Bin1 (see Figure 3a) . Similarly,¯ow cytometric analysis of cells harvested 48 h after viral infection showed that Ad-Bin1DBAR-C did not elicit DNA degradation, even at elevated multiplicities of infection (see Figure 3b ). These observations provided additional evidence that the cytotoxic eects of Bin1 in HepG2 cells were not due to some nonspeci®c cause, since overexpression of a loss-of-function mutation that eliminated tumor suppressor properties also abolished PCD activity. We concluded that Bin1 engaged a PCD process that could explain the basis for its tumor suppressor properties. p53 and Rb are dispensable for PCD by Bin1 p53 has a central role in many types of PCD but it is mutated in many cancers. The retinoblastoma protein (Rb) has been reported to be antiapoptotic in many systems but in some cases it also has proapoptotic roles (Bowen et al., 1998; Day et al., 1997) . The central importance of p53 and Rb in PCD control prompted us to determine whether these genes were needed for Bin1 action. HepG2 cells have wild-type p53 and Rb genes, so we examined the eect of Ad-Bin1 on another tumor cell line, SAOS-2 osteosarcoma, which has homozygous deletions in both genes. SAOS-2 cells were infected with 100 m.o.i. Ad-LacZ or Ad-Bin1 virus and expression was con®rmed by b-galactosidase staining or Western blotting, respectively (data not shown). Parallel dishes of cells were examined for the appearance of morphological features of apoptosis or harvested and processed for TUNEL labeling and¯ow cytometry. Similar to its eects on HepG2, Ad-Bin1 caused cell rounding, plasma membrane deformations, and substratum detachment (Figure 4a ). Flow cytometry showed an increase in the number of TUNELpositive cells with sub-G1 phase DNA following AdBin1 infection. Positive cells emerged from all phases of the cell cycle and kinetics were similar to those observed in HepG2 cells (see Figure 4b) . These results were consistent with evidence that p53 is dispensable for PCD by c-Myc in epithelial cells (Sakamuro et al., 1995; Trudel et al., 1997) and with ®ndings in breast cancer and melanoma cell lines that p53 status was not correlated with Bin1 susceptibility (Ge et al., 1999 (Ge et al., , 2000a . Consistent with the SAOS-2 susceptibility, the results of extensive RNAse protection and Western analyses of HepG2 cells expressing Bin1 did not reveal any dierences in the expression of a variety of cell cycle and apoptosis regulators, including p53, Rb family members, cell cycle-dependent kinase inhibitors (p16INK4, p14ARF, p21WAF1, p27KIP1, or p57KIP2), or Bcl-2 family genes (Bcl-2, Bcl-X L , Mcl-1, Bik, Bax, or Bak). We concluded that Bin1 acted independently of the p53 and Rb pathways.
Bin1 does not activate caspases
The type of PCD process elicited by Bin1 was further characterized by examination of nuclear phenotypes associated with caspase activation. HepG2 cells infected with Ad-Bin1 but not Ad-LacZ displayed signs of nuclear deformation and chromatin margination at the nuclear periphery and at focal sites in the nucleoplasm (see Figure 5a ). However, cells maintained considerable genomic DNA integrity and there was no evidence of nuclear lamina breakdown. This phenotype was dierent from that seen in classical or type I apoptosis, which is associated with a distinct nuclear condensation phenotype, and suggestive of type II apoptosis in which cytosolic features predominate. The contrast in nuclear morphology was highlighted by comparison to the nuclear phenotype elicited by the protein kinase inhibitor staurosporine, which induces type I apoptosis (see Figure 5a , right panel). Transient transfection of HepG2 cells with Bin1 plasmid vectors elicited the same nuclear phenotype as Ad-Bin1, ruling out a nonspeci®c adenovirus vector artifact (data not shown). To determine whether Bin1 caused nucleosomal DNA cleavage (`DNA laddering'), genomic DNA was isolated from cells infected with adenoviral vectors or treated with staurosporine and fractionated by agarose gel electrophoresis. Genomic DNA degradation was observed in cells infected by Ad-Bin1 but not by Ad-lacZ (see Figure 5b , left panel). This result was consistent with the ability of Bin1 to induce positive TUNEL reaction. However, Bin1 did not induce nucleosomal DNA cleavage, even though this feature could be induced in HepG2 cells by staurosporine (see Figure 5b , right panel).
The caspase-3 activated nuclease DFF/CAD is primarily responsible for nucleosomal DNA degradation and chromatin collapse, which is a characteristic of classical or type I apoptosis (Enari et al., 1998; Liu et al., 1997; Woo et al., 1998) . The absence of these features suggested that Bin1 did not activate caspase-3. To con®rm this likelihood, caspase-3-like activities were assayed in extracts from Ad-Bin1-infected cells by measuring cleavage of the¯uorescent substrate Ac-DEVD-pNA (see Figure 5c ). Cleavage of Ac-DEVDpNA by caspase-3-like activity was monitored by absorbance at 405 nM measured at various times after addition to extracts. Exogenous recombinant caspase-3 was used as a positive control for the assay. As expected, staurosporine induced caspase-3-like activity in cell extracts. This induction con®rmed that HepG2 cells expressed pro-caspase-3-like enzymes that were competent for activation by apoptotic stimuli, in support of evidence of a predominent role for caspase-3 in classical apoptotic responses in HepG2 cells (Suzuki et al., 1998) . In contrast, no signi®cant cleavage of Ac-DEVD-pNA occurred in extracts prepared from cells infected with Ad-Bin1 or Ad-LacZ. In Western blotting experiments, we also did not detect proteolytic cleavage of either pro-caspase-3 or the caspase-3 substrate PARP (data not shown).
One possibility was that Bin1 activated a caspase other than caspase-3. To assess this possibility, we tested whether Bin1-induced cell death was suppressed by ZVAD.fmk, a broad spectrum inhibitor of caspases. In these experiments, the relative number of cells displaying sub-G1 phase DNA by¯ow cytometry was used as a measurement of PCD. As expected, ZVAD.fmk signi®cantly blocked staurosporine-induced cell death. In contrast, ZVAD.fmk did not aect PCD by Bin1 even when added at high concentrations (see Figure 5d ). Taken together, these results argued that the death process activated by Bin1 was caspaseindependent.
To con®rm this conclusion and gain additional insight into this death process we examined cells by electron microscopy. These experiments revealed cytosolic features consistent with a programmatic death process such as type II apoptosis (see Figure 6 ). AdlacZ-infected cells showed no signs of cytopathology.
In contrast, staurosporine-treated cells were shrunken and exhibited cytosolic vacuolation, chromatin condensation, and nuclear degeneration (plasma membrane blebs were also observed but were not so dramatic in this cell system). Ad-Bin1-infected cells were similarly shrunken and heavily vacuolated. Margination of chromatin at the nuclear periphery was evident. However, there was no nuclear degeneration and limited chromatin condensation by comparison to staurosporine-treated cells. Cell nuclei were shrunken relative to Ad-LacZ-infected cells but not so severely as staurosporine-treated cells. Strikingly, the nuclear lamina in Ad-Bin1-infected cells remained essentially intact. This feature supported the lack of caspase involvement because lamins are subjected to caspase-mediated proteolysis during PCD (Lazebnik et al., 1993; Rao et al., 1996) . In addition, lamin cleavage is separable from chromatin collapse (Lazebnik et al., 1995) but is important for complete nuclear degeneration (Rao et al., 1996) , so the more limited nuclear degeneration in Ad-Bin1-infected cells was also consistent with a caspase-independent process. We observed no`exploded' cells or¯occulent densities in organelles or the cytosol that would signal necrosis. Trials in which ZVAD.fmk was added con®rmed that the PCD phenotype induced by Bin1 was not aected by caspase inhibition. Addition of 100 mM ZVAD.fmk reduced cell volume and induced the appearance of focal densities in the nucleus, but these features were a nonspeci®c artifact of ZVAD.fmk, because the same features were also apparent in Ad-LacZ-infected cells. Interestingly, ZVAD.fmk did not block the Bin1 phenotype, in which cytosolic vacuolization predominated. In contrast, ZVAD.fmk dramatically aected the phenotype of staurosporine-treated cells, reversing nuclear degradation to a large extent. We concluded that Bin1 engaged a PCD process that was caspaseindependent yet associated with limited chromatin degradation and cytosolic features of PCD.
Cell death by Bin1 is not blocked by Bcl-2 or Fas pathway inhibition
To further delineate the death process activated by Bin1 we investigated links to two classical PCD regulatory pathways. Bcl-2 proteins inhibit caspase activation through their ability to in¯uence mitochondrial physiology, whereas death receptors directly activate caspases (Ashkenazi and Dixit, 1998; Thompson and Vander Heiden, 1999) . HepG2 cell lines overexpressing Bcl-2 or a dominant inhibitor of FADD, which blocks Fas signals (Muzio et al., 1996) , were tested for response to Ad-Bin1. One would predict the response would be unaected by Bcl-2 or Fas pathway disruption if Bin1 acted in a caspase-independent manner. Cells overexpressing Bcl-2 were resistant to staurosporine-induced apoptosis relative to vector control cells (data not shown). In contrast, there was no dierence in the susceptibility of cells overexpressing Bcl-2 or the FADD dominant inhibitor to death induction by Bin1 (see Figure 7a) . On a dierent line of work, we had observed that recombinant Bin1 baculoviruses increased the kinetics of cell death in Sf9 cells, and that Bcl-2 could not inhibit this eect (see Figure 7b) , despite the fact that Bcl-2 inhibits baculovirus-induced cell death in this (Alnemri et al., 1992) . In support of these results, we also obtained a set of negative results from experiments aimed at determining whether Bin1 caused cytochrome c release or altered mitochondrial membrane potential (data not shown). In summary, we concluded that Bin1 acted via non-classical mechanisms that were independent of the Bcl-2 and Fas pathways, two chief regulators of caspases in cells.
SV40 T antigen inhibits induction of cell death by Bin1
In previous work, we found that Bin1 inhibited Ras cotransformation of primary rodent ®broblasts by c-Myc and adenovirus E1A but not by SV40 large T antigen (Elliott et al., 1999; Sakamuro et al., 1996) . Since Bin1 activated a PCD process in malignantly transformed human cells we hypothesized that T antigen might suppress these eects. This hypothesis was not invalidated by the ®nding that p53 and Rb were dispensable for Bin1-induced death, because T antigen has additional role(s) in immortalization and human cell transformation beyond inactivation of these tumor suppressors (Conzen and Cole, 1995; Hahn et al., 1999; Powell et al., 1999) . The eects of T antigen were examined using WI-38 diploid ®broblasts and a WI-38 derivative that expresses T antigen (WI-38/T cells). Like HepG2, WI-38 cells are functionally null for Bin1, in this case due to a missplicing event which causes loss-of-function identical to that which occurs in Bin1 in melanoma (Ge et al., 1999) . Western analysis con®rmed RT ± PCR results (Wechsler-Reya et al., 1997b) establishing missplicing of brain-speci®c exon 12A in WI-38 cells and also in the WI-38/T derivative. The 12A isoform exhibited reduced mobility on SDS gels relative to wild-type Bin1 (see Figure 8a , top panel) and was also recognized by a monoclonal antibody that is speci®c for exon 12A-encoded residues (Ge et al., 1999 ) (see Figure 8a , bottom panel).
T antigen blocked susceptibility to cell death by Bin1 (see Figure 8b ,c). Loss of viability occurred only if Ad-MABin1 was induced by coinfection with Adcre virus. Death correlated with the appearance of rounded, detached cells similar to the cytopathic seen Extracts were prepared and assayed for the presence of caspase-3-like activity using the colormetric substrate Ac-DEVD-pNA. Reactions were monitored for production of cleavage product at 405 nm at the times indicated. Recombinant caspase-3 was used as a positive control. (d) Caspase inhibition does not block Bin1-induced cell death. HepG2 cells were infected with 100 m.o.i. Ad-Bin1 or treated with 0.5 mM staurosporine in the presence or absence of the caspase inhibitor ZVAD.fmk at the concentration indicated. Cells were harvested 36 h later and processed for¯ow cytometry. The graph shows the relative proportion of the cell population undergoing cell death, using the appearance of sub-G1 phase DNA as an indicator Bin1 induces caspase-independent PCD K Elliott et al in HepG2 and other malignant cell lines (Ge et al., 1999 (Ge et al., , 2000a . This response con®rmed that the missplicing and inactivation of Bin1 in WI-38 was functionally meaningful. Similar results were obtained using derivatives of HepG2 that were engineered to express T antigen gave (data not shown). To con®rm that endogenous misspliced isoform in WI-38 was truly a loss-of-function alteration, we infected cells with an adenoviral vector expressing this isoform (AdMABin1-10+12A) (Ge et al., 1999) . No loss of viability or cell detachment was observed. We concluded that SV40 T antigen suppressed PCD by Bin1.
A serine protease implicated in PCD by c-Myc inhibits DNA degradation by Bin1
The serine protease inhibitor AEBSF (4-(2-aminoethyl) benzenesulfonyl¯uoride) has been reported to inhibit c-Myc-induced death in Rat1 ®broblasts (Kagaya et al., 1997) . This report also indicated that AEBSF does not block apoptosis induced by Fas activation, the cytotoxic T cell granule protein granzyme B, or a variety of cytotoxic drugs, nor did other kinds of serine protease inhibitors aect death by c-Myc. Thus, AEBSF was a relatively speci®c inhibitor of a feature of the death process(es) induced by c-Myc. We reasoned that if there was any overlap in the mechanisms used by Bin1 and c-Myc, then AEBSF might aect the death process activated by Bin1. To test this notion, HepG2 cells were infected with AdLacZ or Ad-Bin1, or treated with staurosporine, and then left untreated or treated with AEBSF or its inactive analog AEBSA (4-(2-aminoethyl)benzenesulfonamide). Flow cytometery was used to monitor the appearance of sub-G1 phase DNA as a measurement of PCD. In contrast to ZVAD.fmk, AEBSF suppressed Bin1-induced DNA degradation to the background levels seen in cells infected with Ad-LacZ (see Figure  9 ). This suppression re¯ected inhibition of a serine protease(s), rather than some nonspeci®c eect, because the inactive compound AEBSA was ineective. Consistent with previous ®ndings that AEBSF is not a general inhibitor of apoptosis (Kagaya et al., 1997), (Ge et al., 1999) . The arrow indicates a polypeptide including exon 12-derived residues in WI-38 and WI-38/T that has identical mobility to the aberrant Bin1-10+12A splice isoform expressed in human melanoma (Ge et al., 1999) . ( under the same conditions where AEBSF suppressed the action of Bin1 it did not suppress DNA degradation induced by staurosporine (the eects of which were actually accentuated by AEBSF treatment). Thus, AEBSF speci®cally inhibited DNA degradation by Bin1. We concluded Bin1 acted in part through activation of a serine protease, similar to c-Myc, in support of the conclusion that Bin1 and c-Myc shared certain PCD mechanisms.
Discussion
Bin1 activated a PCD process in malignant cells
This study de®nes a function for the BAR family adaptor protein Bin1 in a caspase-independent PCD process that limits neoplastic transformation. Bin1 function is complex and regulated by alternate splicing. Splice isoforms that interact with c-Myc have tumor suppressor properties and are missing or inactivated in breast carcinoma, metastatic prostate cancer, and malignant melanoma (Ge et al., 1999 (Ge et al., , 2000a Sakamuro et al., 1996) . The results of this study suggest that the antineoplastic eects of these Bin1 isoforms in malignant cells are a consequence of their ability to activate PCD. Caspase-independent death processes where cytosolic features predominate without accompanying classical nuclear phenotypes have been termed type II apoptosis. The mechanisms underlying this type of PCD are poorly understood. Two other cancer suppression genes, Pml and CD47, have been reported to activate suicide programs with similar features. Pml is a nuclear dot-associated protein that is disrupted in acute promyelocytic leukemia. Expression of wild-type Pml in malignant cells engages a death program with features similar to that engaged by Bin1 (Quignon et al., 1998) . CD47 is a receptor for the antiangiogenic extracellular matrix protein thrombospondin. CD47 ligation engages a death program on chronic lymphocytic leukemia cells (Mateo et al., 1999) . It is unclear whether these programs share any common aspect. Nevertheless, such caspase-independent processes may be important because they are evolutionarily ancient:`classic' apoptotic regulators such as CED-4, Bak, and Bax elicit death in yeast, with vacuolation phenotypes similar to those seen in metazoan cells, despite the fact that yeast lacks caspases (Ink et al., 1997; James et al., 1997; Jurgensmeier et al., 1997; Xiang et al., 1996) . Such programs may be integrated yet distinct from apoptosis, which apparently evolved later in metazoan cells.
Independence from mitochondrial processes and caspases
We found that PCD by Bin1 was not subject to suppression by Bcl-2 or to inhibition of the Fas pathway and that cellular demise was not associated with mitochondrial alterations. These observations were internally consistent given that the death process was caspase-independent. However, they were unexpected given that Bin1 interacts with c-Myc, which activates classical apoptosis by eliciting cytochrome c release and subsequent caspase activation (Juin et al., 1999) . Two important issues impact consideration of this apparent conundrum. First, it seems likely that c-Myc acts in a complex manner to induce death. Cytochrome c release has been shown to be an important component of the process activated by c-Myc, but this event is apparently insucient (Juin et al., 1999) . In addition, as noted above, careful investigations have shown that neither Bcl-2 nor caspase inhibitors block the death commitment decision induced by c-Myc, but rather the phenotype and kinetics of the execution step (McCarthy et al., 1997) . Interestingly, caspase-independent suicides that occur retain the cytosolic but not the nuclear features of classical apoptosis (McCarthy et al., 1997) , not unlike the death phenotype induced by Bin1. It is important to draw a distinction between the mechanisms which aect death kinetics and those which aect death commitment decisions, because in slow growing tumors where c-Myc is overexpressed (such as many carcinomas) the eects of Bcl-2 or other antiapoptotic signals may be insucient to provide adequate escape from the death penalty that is associated with c-Myc overexpression. If this is the case, there would be a selection for loss of caspaseindependent processes that impact execution and that are separate from the mitochondrial and death receptor axes.
A second issue is the possibility that caspaseindependent steps are required for apoptotic outcomes by c-Myc or other proapoptotic stimuli. A precedent for this concern is raised by studies of the tumor suppressor Pml, which activates caspase-independent death in tumor cells but which is also necessary for apoptosis induced by a wide variety of death stimuli (Quignon et al., 1998; Wang et al., 1998) . It is interesting that the death processes used by c-Myc or Bin1 are each susceptible to inhibition at some level by AEBSF, a serine protease inhibitor which does not generally aect apoptosis (Kagaya et al., 1997) . Serine death proteases and caspases appear to act in various cells in dierent but integrated hierarchies (Kagaya et al., 1997; Wright et al., 1997) , so the fact caspases are dierentially activated by c-Myc and Bin1 supports the notion of more than one death signal emerging from cMyc. Results from our laboratory using dominant Figure 9 Implication of a serine protease(s) in programmed cell death by Bin1. HepG2 cells were infected with 100 m.o.i. Ad-Bin1 or Ad-LacZ or treated with 0.5 mM staurosporine and left untreated or treated additionally with 0.4 mM AEBSF or its inactive analog AEBSA. Cells were processed for¯ow cytometry 24 h later. The graph presents the relative proportion of the cell population exhibiting sub-G1 phase DNA. The mean and standard error of three trials is shown inhibitory and antisense approaches support the possibility that Bin1 may be necessary for apoptosis by c-Myc (unpublished observations). However, due to the unusual caspase-independent nature of the Bin1 death phenotype in malignant cells, we are addressing this question further using cells targeted for Bin1 gene deletion. In summary, despite the key role of apoptotic escape in malignant development, it is notable that caspases and other apoptosome components may be inactivated in cancer cells less frequently than caspaseindependent functions such as Pml or Bin1 (Ge et al., 1999 (Ge et al., , 2000a Mu et al., 1994; Sakamuro et al., 1996; Zhang et al., 2000) . Our ®ndings suggest that Bin1 participates in some caspase-independent process which can in¯uence cell death commitment in malignant cells.
Susceptibility to inhibition by SV40 T antigen
We found that the death process activated by Bin1 was susceptible to suppression by SV40 large T antigen. The ability of this tumor virus protein to block the death process supported the notion that its inactivation is relevant to cancer development. This result was also consistent with earlier ®ndings that transformation of rodent ®broblasts by T antigen is not subject to suppression by Bin1 (Sakamuro et al., 1996) . This observation does not con¯ict with the ®nding that Bin1 acts independently of p53 and Rb, because there is evidence that T antigen acts beyond inactivating p53 and Rb in immortalization and human cell transformation (Conzen and Cole, 1995; Hahn et al., 1999; Powell et al., 1999) . For example, T antigen cooperates with activated Ras and the telomerase catalytic subunit TERT to cause malignant transformation of human cells, and one can not complement the eects of T antigen by coexpression of the human papilloma virus E6 and E7 proteins (Hahn et al., 1999) , which inactivate p53 and Rb, respectively. In this context, it is interesting to note that before the discovery of TERT the rare successes achieved in immortalizing human cells were achieved usually with T antigen or SV40 DNA. Interestingly, Bin1 is inactivated by missplicing in diploid WI-38 cells in the same manner as in malignant melanoma (Ge et al., 1999) and this event makes them susceptible to killing by Bin1, unlike IMR diploid ®broblasts. Thus, Bin1 activation may be relevant to WI-38 biology, perhaps aecting some process also targeted by T antigen.
Bin1 function
Bin1 has two functions that are varied by alternate splicing. The most signi®cant alterations in Bin1 occur in brain. Brain isoforms localize to clathrin-coated vesicles and promote synaptic vesicle endocytosis, like amphiphysin, by recruiting enzymes that modify lipids and alter membrane structure (Wigge and McMahon, 1998) . In contrast, the ubiquitous Bin1 isoforms lack sequences needed for targeting to clathrin-coated vesicles (Ramjaun and McPherson, 1998) and instead exhibit nuclear localization (Elliott et al., 1999; Wechsler-Reya et al., 1997a , 1998 . The c-Mycinteracting isoform analysed in this study did not aect endocytosis under conditions where it activated cell death. Preliminary examination of Bin1-10, a closely related c-Myc-interacting isoform, suggest it has similar properties (unpublished observations). In contrast, isoforms that include brain exon 12A did not induce death, consistent with previous results (Ge et al., 1999) . Thus, we believe that the death induction function of Bin1 is a unique feature of isoforms that can localize to the nucleus and interact with c-Myc. Bin1 isoforms form heterodimers in the brain (Wigge et al., 1997) . Therefore, it is tempting to speculate that the endocytosis connection in neurons re¯ects a specialized link in those cells between survival and the achievement of a synaptically active state, which would be associated with neurotransmitter release and hence endocytotic membrane tracking.
From a functional standpoint, although ubiquitous Bin1 isoforms are not amphiphysin-like, the high conservation between amphiphysin and the ubiquitous Bin1 isoforms nonetheless suggest a functional connection to membrane dynamics at some level (perhaps related to internal vesicle dynamics). The BAR domain comprises the major part of this conservation. This domain is crucial for death activity but what it does is currently obscure. A membrane connection is intriguing in light of emerging interest in possible connections between autophagy and apoptosis (Thompson and Vander Heiden, 1999) . However, we have not observed any death inhibitory eects of 3-methyladenine, a classical inhibitor of autophagy (unpublished observations). Nevertheless, there is certainly a precedent for a nucleocytosolic adaptor protein that has dual functions in transcriptional regulation and membrane dynamics. CtBP/BARS is an adaptor protein initially identi®ed through its ability to interact with and inhibit the tumorigenic activity of adenovirus E1A (Schaeper et al., 1995) . CtBP/BARS binds to cell cycle and transcriptional regulatory complexes (Meloni et al., 1999; Sewalt et al., 1999; Sollerbrant et al., 1996) but it also controls membrane vesiculation in the Golgi complex (Weigert et al., 1999) . Parallels between CtBP and Bin1 are intriguing given their connections to E1A and c-Myc, which are biologically distant cousins. A complex nature for Bin1, like that exhibited by CtBP/BARS, would not be out of step with the complex and still largely obscure nature of c-Myc, which has a highly integrated cell regulatory function.
We did not detect any changes in the expression of several target genes linked to apoptosis by c-Myc, including ornithine decarboxylase, CDC25A, or Fas ligand (Galaktionov et al., 1996; Hueber et al., 1997; Packham and Cleveland, 1994) , but no target gene identi®ed to date has been assigned an unambiguous role in apoptosis (Dang, 1999; Evan and Littlewood, 1998) . In transient assays, Bin1 can suppress c-Myc transactivation and repress transcription when tethered to DNA (Elliott et al., 1999) . It is unclear whether these activities are physiologically germane; if they are epiphenomenon of Myc-Bin1 interaction transient assays, then Bin1 may have a signaling role that is unaliated with transactivation. The latter possibility can be entertained since not all biological actions of cMyc can be ascribed strictly to gene regulation (Gusse et al., 1989; Lemaitre et al., 1995; Li et al., 1994; Prendergast and Cole, 1989; Yang et al., 1991) and because Bin1 more resembles a signaling protein than a transcription factor. Based on existing data, we have suggested that PCD by c-Myc involves distinct Bin1 induces caspase-independent PCD K Elliott et al `priming' and`triggering' steps, the former of which is associated with gene regulation but the latter of which is not (Prendergast, 1999) . Further investigations are required to unravel the physiological relationship between Bin1 and the proapoptotic and transcriptional properties of c-Myc.
Bin1, cell death, and cancer
Cancer is characterized by dysfunctional adhesion and cell survival signaling. Our ®ndings suggest that loss of Bin1 may eliminate one mechanism which can limit the consequences of inappropriate activation of c-Myc or other oncogenes. Suicide mechanisms are progressively eliminated during neoplastic progression (Williams, 1991) , and in invasive breast cancers and metastatic prostate cancers where Bin1 losses occur frequently (Ge et al., 2000a,b) there is strong evidence that loss of cell suicide capacity corresponds with malignant conversion (Kyprianou et al., 1990 (Kyprianou et al., , 1991 McDonnell et al., 1992) . However, malignant conversion is associated generally with altered adhesive capabilities that facilitate invasion and metastasis. Resistance to anoikis (adhesion deprival-induced cell suicide) is likely to be a crucial feature of the pathophysiology of epithelial malignancy. Interestingly, cell death by many oncogenes including c-Myc is suppressed by integrin signaling (Crouch et al., 1996) , and Bin1 has been reported to interact with certain a-integrins (Wixler et al., 1999) . The interaction between Abl kinase and Bin1 in cells (Kadlec and Pendergast, 1997 ) may be consistent with an integrin connection, given evidence that Abl can become activated at focal adhesions where integrins are localized (Lewis et al., 1996; Taagepera et al., 1998) . Therefore, further investigation of the links between Bin1-dependent cell death and integrin signaling may provide insights into the signi®cance of Bin1 losses in cancer as well as to mechanisms that govern cell death induction by c-Myc and other oncogenes.
Materials and methods
Recombinant adenoviruses
Constitutive and inducible adenoviral vectors were developed by standard methods. The constitutive virus Ad-Bin1 contained Bin1 cDNA driven by a cytomegalovirus (CMV) enhancer-promoter in place of the E1 region of the virus. Brie¯y, the full-length Bin1 cDNA 99fE, that includes exons 1 ± 11 and 13 ± 16 but not brain-speci®c exons 12A ± 12D (Sakamuro et al., 1996; Wechsler-Reya et al., 1997b) , was subcloned into pAdCMVlink-1. 293 cells were cotransfected with this derivative plus ClaI-digested dl7001 adenovirus DNA to obtain the recombinant virus by homologous recombination as described (Davis and Wilson, 1996) . Similar viral vector constructions used Bin1-10+12A isoform, an aberrant tumor-speci®c and loss-of-function isoform (Ge et al., 1999) , or Bin1DBAR-C, a loss-of-function deletion mutant lacking a.a. 126 ± 207 (Elliott et al., 1999b) . Plaquepuri®ed clones were identi®ed by Southern and Western analysis and the DNA sequence of the insert was determined to verify wild-type status. A variation of up to several hours was noted in the kinetics of death induction by dierent preparations of Ad-Bin1. The inducible virus Ad-MABin1 was constructed similarly in a cre-loxP adenoviral system kindly provided by FL Graham (Anton and Graham, 1995) . Brie¯y, the luciferase cDNA in the vector pMA19 (Anton and Graham, 1995) was replaced with the 99fE cDNA. The resulting plasmid was cotransfected into 293 cells as above to obtain the recombinant virus by homologous recombination. In this virus, the Bin1 cDNA is conditionally expressed under the control of the cytomegalovirus (CMV) promoter, from which it is separated by an loxP-¯anked stuer sequence. Bin1 expression is suppressed in the unrearranged virus because the stuer region includes stop codons in all three reading frames. The analogous Ad-MA19 virus, which expresses luciferase, was a gift of FL Graham. In cells expressing P1 bacteriophage Cre site-speci®c recombinase, the intervening stuer region is removed by Cre-mediated excision, leading to expression of the transgene. Ad-vect is a control adenovirus kindly provided by JM Wilson which is similar in structure to the others except that it contains no transgene (Davis and Wilson, 1996) .
Cell culture
HepG2, SAOS-2, and 293 cell lines were maintained in Dulbecco's modi®ed Eagle's media (DMEM) supplemented with 10% fetal bovine serum (Gibco) and 50 U/ml penicillin and streptomycin (Fisher). For adenovirus infections, HepG2 or SAOS-2 cells were plated at 5610 5 cells per 6 cm culture dish and allowed to recover overnight. Virus was added to the cells at the indicated m.o.i. in a volume of 1 ml of DMEM supplemented with 2% fetal bovine serum and allowed to adhere for 2 ± 3 h at 378C. Cells were then washed and fed with DMEM 10% FBS. Where appropriate, the indicated concentrations of the broad spectrum caspase inhibitor ZVAD.fmk (Enzyme Systems Products) was added to cells at the time of infection and maintained until harvesting. Thapsigarin and staurosporine (Calbiochem) were used as chemical inducers of apoptosis at concentrations of 2 and 0.5 mM, respectively, and as positive controls produced similar results. For cell viability determinations, cells were harvested 48 h postinfection by trypsinization, washed in PBS, stained with trypan blue and counted using a hemacytometer. Where indicated, the serine protease inhibitor 4-(2-aminoethyl)-benzenesulfonyl¯uoride (AEBSF) (Sigma) or its inactive analog 4-(2-aminoethyl)benzenesulfonamide (AEBSA) (Aldrich), which substitutes an amino group for the crucial¯uoride moiety in AEBSF. Both inhibitors were added to cells at infection and maintained at a ®nal concentration of 0.4 mM, a concentration which is nontoxic but sucient to suppress c-Myc-mediated apoptosis (Kagaya et al., 1997) . For electron microscopy, HepG2 cells were infected with Ad-LacZ or Ad-Bin1 (m.o.i.=100) or treated with 0.5 mM staurosporine and where indicated treated with 100 mM ZVAD.fmk. Adherent and¯oating cells were harvested 36 h after adenoviral infection or 24 ± 30 h after staurosporine treatment and processed for osmium tetroxide staining and electron microscopy using standard methods. Baculovirus experiments were performed in the insect cell line Sf9 using full-length recombinant viruses expressing Bin1, Bcl-2 or no insert, essentially as described (Alnemri et al., 1992; Elliott et al., 1999b) . Viable cell counts were determined at the indicated times after virus infection by the trypan blue exclusion method.
Western analysis
Cell lysates was prepared and analysed by standard protocols (Harlow and Lane, 1988) . Brie¯y, lysates were fractionated by SDS ± PAGE, gels were electrophoretically transferred to ECL membrane (Amersham) or Immobilon-P (Millipore). Blots were blocked in 3% skim milk and probed with antiBin1 monoclonal antibodies 99D, 99I or a12A, or anti-Bcl-2 antibody #124 (DAKO). 99D and 99I recognize epitopes in the c-Myc binding domain encoded by exon 13 whereas a12A recognizes an epitope encoded by brain-speci®c exon 12A (Wechsler-Reya et al., 1997a; Ge et al., 1999). Antibodies were diluted 1 : 50 in PBS with 2.5% skim milk and 0.1% Tween-20 and incubated with the membrane 12 h at 48C. Blots were washed and incubated 1 h in the same buer with secondary goat anti-mouse antibodies conjugated to horseradish peroxidase (BMB) and developed using a chemiluminescence kit using the protocol suggested by the vendor (Pierce).
Immunofluorescence
Cells were seeded on coverslips and the next day infected with recombinant adenoviruses or treated with drugs. After the periods indicated cells were washed twice with PBS, stained 5 min with 5 mg/ml Hoechst 33323 (Sigma) dissolved in PBS, and analysed immediately by immuno¯uorescence. For endocytosis assays, cells seeded on coverslips were infected with recombinant adenoviruses and 20 h later processed for¯uid-phase uptake or receptor-mediated endocytosis as described (Barbieri et al., 1998; Benmerah et al., 1998) . Brie¯y, cells were incubated 30 min in serum-free DMEM and then treated with 100 nM¯uorescein-conjugated transferrin (Sigma) (receptor-mediated) or 2 mg/ml horseradish peroxidase (Sigma) in 0.2% BSA (¯uid-phase). After incubation for 15 min, cells were cooled to 48C, washed 26 with ice-cold PBS, and ®xed in 3.7% paraformaldehyde. Cells were mounted for analysis by confocal¯uorescence microscopy or processed with horseradish peroxidase substrate before microscopic analysis.
Flow cytometry
Cells were harvested by trypsinization and ®xed in 1% paraformaldehyde and then 80% ethanol. TUNEL assay was performed by incubating samples 1 h at 378C in TdT reaction buer (Boehringer Mannheim) and then staining 30 min at room temperature with¯uoresceinated streptavidin (DuPont). Cells were then incubated 30 min at room temperature with propidium iodide. Alternatively, to analyse only DNA degradation, cells were ®xed in 70% ethanol and permeabilized in PBS/0.2% Tween-20 followed by propidium iodide staining as described (Sakamuro et al., 1997) . Flow cytometry was performed on a EPIC/XL cell analyser (Coulter).
Nucleosomal DNA assay Genomic DNA was prepared by a modi®ed Hirt method (Debbas and White, 1993; Hirt, 1967) or by the following method, as indicated. Cells were gently resuspended in 250 ml TBE buer (90 mM Tris-borate/2 mM EDTA) containing 0.4% NP40 and 5 mg RNAse A and incubated 30 min at 378C. Proteinase K and SDS were added to 100 mg/ml and 1% (v/v), respectively, and samples were incubated overnight at 558C. Genomic DNA was extracted with phenol-chloroform, precipitated with ethanol, and fractionated by agarose gel electrophoresis.
Caspase activity assay
Lysates prepared from equivalent numbers of cells were used to assess caspase-3-like activities, employing the Quantizyme Assay System as recommended by the vendor (Biomol Research Laboratories). Brie¯y, duplicate plates were harvested 48 h post-infection, one for cell counts and the other for cell lysates. 5610 7 cells/ml were extracted in the cell lysis buer provided by the vendor and 10 ml of extract was used in reactions to monitor cleavage of the substrate Ac-DEVD-pNA. Reactions were examined at various times after addition of the substrate by spectroscopy at 405 nM to monitor release of the product. Data were analysed with DeltasoftII Software (Biometallics Inc.).
